inVibe’s Labs Introduces TrialPulse
inVibe’s Labs introduces TrialPulse, a technology platform that helps integrate patient insights within the drug development process.
TrialPulse brings patient insights to clinical teams across six important areas, including the patient experience, disease burden, unmet needs, trial design, recruitment, and retention optimization. The innovative market research platform works by virtually recruiting a sample of real patients similar to the study's inclusion/exclusion criteria, then providing them with relevant stimuli (e.g., protocol summaries, e-consent forms, recruitment materials), and prompting them to provide candid feedback via inVibe's proprietary automated voice response (AVR) interview platform.
TrialPulse works by collecting all of the patient voice data, then analyzing it with a combination of human linguistic expertise and advanced machine learning technology, explained by this video. The interactive, searchable, filterable online portal enables our clients to listen to the actual voice responses, share audio clips with other team members and researchers, and/or simply review the high-level executive summary and visual reports created by inVibe analysts.
More on TrailPulse
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
